ESMO Congress 2022

More needs to be done in renal cancer

More needs to be done in renal cancer

Up to 90% of patients will die from metastatic disease and the search for biomarkers lags behind other tumour types, says ESMO Lifetime Achievement Award 2022 winner Prof. Bernard Escudier  

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.